Healio

First-line combination should be ‘new standard’ in advanced lung cancer

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Healio

First-line immunotherapy underutilized in kidney cancer; ‘different mechanisms’ needed

Please provide your email address to receive an email when new articles are posted on . Immune checkpoint inhibitor-based combinations are the preferred first-line therapy for metastatic clear cell ...
Cure Today

First-Line Enhertu Combo Gets Priority Review in HER2+ Metastatic Breast Cancer

Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
ascopubs.org

Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
The American Journal of Managed Care

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression. The phase 3 RATIONALE-306 study demonstrated ...
Cure Today

NCCN Names Trodelvy a Preferred First-Line Treatment for Metastatic TNBC

NCCN upgrades Trodelvy to category 1 preferred first-line therapy for metastatic TNBC with CPS <10 and no germline BRCA1/2 mutation. For PD-L1–positive metastatic TNBC (CPS ≥10), Trodelvy plus ...
FiercePharma

Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer (TNBC), Gilead Sciences’ Trodelvy ...
Medscape

Osimertinib's Benefits in NSCLC Can Extend Beyond First Line

Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...